Gene Therapy Market - Top Companies and Manufacturers

Companies Dominating the Gene Therapy Landscape

The introduction of new medicines, technologically sophisticated product launches, regulatory approvals, acquisitions, and joint ventures with other businesses are the activities of major players in the global market. These tactics are probably going to encourage the worldwide market's expansion.

Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

Biogen Inc.
Gilead Sciences, Inc.
Bristol–Myers Squibb
Alnylam Pharmaceuticals, Inc.
Sarepta Therapeutics, Inc.
Orchard Therapeutics Limited
Celgene Corporation
Spark Therapeutics, Inc.
Sibino GeneTech Co., Ltd.

Browse Key Market Insights with Data Illustration:

Gene Therapy Market Size & Share, Growth Forecasts 2036

In the News

Novartis presented new research demonstrating the transformational and long–term benefits of Zolgensma, a one–time gene therapy for the treatment of spinal muscular atrophy (SMA). The most recent findings from two Long–Term Follow–Up (LTFU) trials, LT–001 and LT–002, reveal that Zolgensma continues to be efficacious and durable across a wide variety of patient demographics, with a positive overall benefit–risk profile.
Biogen Inc. announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending a marketing authorization under exceptional circumstances for QALSODY® for the treatment of adults with amyotrophic lateral sclerosis (ALS) caused by a mutation in the superoxide dismutase 1 gene.

Frequently Asked Questions (FAQ)

In the year 2023, the industry size of gene therapy was over USD 9.4 billion.

The market size for gene therapy is projected to cross USD 98.4 billion by the end of 2036 expanding at a CAGR of 19.8% during the forecast period i.e., between 2024-2036.

The major players in the market are Novartis AG, Biogen Inc., Gilead Sciences, Inc., Bristolâ€“Myers Squibb, Alnylam Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., Orchard Therapeutics Limited, Celgene Corporation, Spark Therapeutics, Inc., Sibino GeneTech Co., Ltd., and others.

The heavy-duty trucks segment is anticipated to garner a share/size of 45% during 2024-2036.

The North America gene therapy sector is poised to hold 37% share by the end of 2036.

Gene Therapy Market - Top Companies and Manufacturers

Companies Dominating the Gene Therapy Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the gene therapy industry?

What is the outlook for the gene therapy market?

Who are the major players dominating the gene therapy landscape?

Which segment will capture the significant market share for gene therapy by 2036?

Which region will provide more opportunities for the gene therapy business in the near future?